File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The past and future of mapping the biomarkers of psychosis

TitleThe past and future of mapping the biomarkers of psychosis
Authors
Issue Date2022
PublisherElsevier Ltd, Current Opinion Journals. The Journal's web site is located at http://www.elsevier.com/locate/copbio
Citation
Current Opinion in Biotechnology, 2022, v. 43, p. 1-5 How to Cite?
AbstractBiomarker research has investigated the neurobiological basis for individual differences in liability to psychosis. However, few biomarkers for psychosis have been consistently found to be useful. This paper reviews several previous approaches to identify putative biomarkers of liability to psychosis, and then highlights the lessons that we have learned. We argue that limiting our research to clinical patients at the extreme of the psychosis continuum would likely obscure our knowledge as to how a minority of the general population would develop psychosis. Research on putative neurobiological origins of inter-individual differences in personality traits may be useful in mapping the biomarkers of psychosis. To identify biomarkers applicable to the general population, we advocate the transdiagnostic and psychosis continuum approach. We also advocate the use of multivariate analyses and computational modelling to tackle complex multi-modal datasets. More research should be conducted to study intra-individual variations over different ranges of timescale. © 2021 Elsevier Ltd
Persistent Identifierhttp://hdl.handle.net/10722/300956
ISSN
2023 Impact Factor: 7.1
2023 SCImago Journal Rankings: 1.813
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, LL-
dc.contributor.authorLui, SSY-
dc.contributor.authorChan, RCK-
dc.date.accessioned2021-07-06T03:12:34Z-
dc.date.available2021-07-06T03:12:34Z-
dc.date.issued2022-
dc.identifier.citationCurrent Opinion in Biotechnology, 2022, v. 43, p. 1-5-
dc.identifier.issn0958-1669-
dc.identifier.urihttp://hdl.handle.net/10722/300956-
dc.description.abstractBiomarker research has investigated the neurobiological basis for individual differences in liability to psychosis. However, few biomarkers for psychosis have been consistently found to be useful. This paper reviews several previous approaches to identify putative biomarkers of liability to psychosis, and then highlights the lessons that we have learned. We argue that limiting our research to clinical patients at the extreme of the psychosis continuum would likely obscure our knowledge as to how a minority of the general population would develop psychosis. Research on putative neurobiological origins of inter-individual differences in personality traits may be useful in mapping the biomarkers of psychosis. To identify biomarkers applicable to the general population, we advocate the transdiagnostic and psychosis continuum approach. We also advocate the use of multivariate analyses and computational modelling to tackle complex multi-modal datasets. More research should be conducted to study intra-individual variations over different ranges of timescale. © 2021 Elsevier Ltd-
dc.languageeng-
dc.publisherElsevier Ltd, Current Opinion Journals. The Journal's web site is located at http://www.elsevier.com/locate/copbio-
dc.relation.ispartofCurrent Opinion in Biotechnology-
dc.titleThe past and future of mapping the biomarkers of psychosis-
dc.typeArticle-
dc.identifier.emailLui, SSY: lsy570@hku.hk-
dc.identifier.emailChan, RCK: rckchan@HKUCC-COM.hku.hk-
dc.identifier.authorityLui, SSY=rp02747-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.cobeha.2021.06.007-
dc.identifier.scopuseid_2-s2.0-85109034485-
dc.identifier.hkuros323347-
dc.identifier.volume43-
dc.identifier.spage1-
dc.identifier.epage5-
dc.identifier.isiWOS:000709360200002-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats